Genvax Technologies, Inc
Genvax Technologies, Inc is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Genvax Technologies, Inc.
Genvax Technologies, Inc is a company.
Key people at Genvax Technologies, Inc.
Genvax Technologies, Inc. is an early-stage biotech startup based in Ames, Iowa, developing next-generation self-amplifying RNA (saRNA) vaccines for animal health. The company creates rapid-response, 100% strain-matched vaccines for production livestock, targeting endemic and emerging diseases like African Swine Fever and swine influenza, while eliminating the need for costly, ineffective traditional vaccine stockpiles.[1][2][4] It serves livestock producers by adapting human healthcare advances—such as saRNA platforms and nanoparticle delivery—to animal applications, addressing zoonotic threats that impact both animal and human health.[2][3]
Founded in 2021, Genvax has demonstrated proof-of-concept in pigs, secured USDA grants for key vaccine developments, and initiated regulatory submissions, positioning it for potential commercialization in 2-3 years.[2]
Genvax Technologies was founded in 2021 by vaccine industry veterans Joel Harris (CEO and co-founder) and Dr. Hank Harris, both serial entrepreneurs who previously built and sold Harrisvaccines to Merck Animal Health in 2015.[2] Drawing from their experience in animal vaccines, the duo launched Genvax to bridge innovations from human mRNA vaccines—proven during COVID-19—back to animal health, where 70% of diseases are zoonotic and rapidly evolving threats like African Swine Fever demand faster solutions.[2]
Early traction includes proof-of-concept studies in pigs, grant funding from USDA-ARS Plum Island Animal Disease Center, Foundation for Food and Agriculture Research (FFAR), and a USDA SBIR grant for swine influenza vaccines, alongside initial USDA product approval submissions.[2]
Genvax rides the mRNA revolution post-COVID, adapting self-amplifying RNA and nanoparticle delivery from human vaccines to animal agriculture, where diseases evolve quickly and impact food security.[2][3] Timing is ideal amid rising zoonotic outbreaks (e.g., African Swine Fever, swine flu), with market forces like USDA funding and regulatory pathways favoring agile platforms over traditional methods.[2]
By enabling precise, on-demand vaccines, Genvax influences the livestock ecosystem, reducing economic losses from disease (billions annually) and supporting sustainability in protein production, while contributing to global One Health initiatives against pandemics.[1][2]
Genvax is poised for milestones in USDA approvals over the next 2-3 years, with grants fueling pipeline expansion into more livestock diseases and potential partnerships like its founders' prior Merck deal.[2] Trends in RNA tech scalability, AI-driven strain matching, and biomanufacturing will accelerate growth, potentially drawing investment from ag-tech VCs amid private market interest.[3]
As zoonotics intensify with climate shifts, Genvax could redefine animal health resilience, scaling from Iowa startup to a Merck-like acquisition target and bolstering the saRNA ecosystem for faster, targeted defenses.
Key people at Genvax Technologies, Inc.
